131117-50-5

Basic information

• Product Name: 4-(1H-Tetrazol-5-ylmethyl)aniline
• Synonyms: 4-(1h-tetrazol-5-ylmethyl)aniline;4-(1H-1,2,3,4-Tetrazol-5-ylmethyl)aniline
• CAS NO: 131117-50-5
• Molecular Formula: C₈H₉N₅
• Molecular Weight: 175.19
• Mol File: 131117-50-5.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 4-(1H-Tetrazol-5-ylmethyl)aniline(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(1H-Tetrazol-5-ylmethyl)aniline(131117-50-5)
• EPA Substance Registry System: 4-(1H-Tetrazol-5-ylmethyl)aniline(131117-50-5)

Safety Data

• Hazardous Substances Data: 131117-50-5(Hazardous Substances Data)

Upstream product

• 3544-25-0 p-aminophenylacetonitrile 
• 18489-25-3 5-benzyl-2H-tetrazole 
• 131090-44-3 5-(p-nitrobenzyl)-tetrazole 

Downstream Products

• 1606973-48-1 N-(4-((2H-tetrazol-5-yl)methyl)phenyl)-4-(3-chlorophenyl)-6-ethyl-1,3,5-triazin-2-amine 
• 1023274-60-3 8-indan-5-yl-5-oxo-2-[4-(1H-tetrazol-5-ylmethyl)-phenylamino]-5,8-dihydro-pyrido[2,3-d]pyrimidine-6-carboxylic acid methoxy-amide 
• 132382-27-5 4-<(2-methyl-1,3,4-oxadiazol-5-yl)-methyl>-phenyl disulfide 
• 119192-13-1 2-methyl-5-(p-acetoxybenzyl)-1,3,4-oxadiazole 
• 119192-14-2 2-methyl-5-(p-hydroxybenzyl)-1,3,4-oxadiazole 
• 119192-12-0 1-(p-hydroxybenzyl)-tetrazole 

Relevant articles and documents

5-OXO-5,8-DIHYDRO-PYRIDO-PYRIMIDINES AS INHIBITORS OF C-FMS KINASE

The invention addresses the current need for selective and potent protein tyrosine kinase inhibitors by providing potent inhibitors of c-fms kinase. The invention is directed to the novel compounds of Formula I: or a salt, stereoisomer, tautomer, crystalline, polymorph, amorphous, solvate, hydrate, ester, prodrug or metabolite form thereof, wherein A, Y, Z, R101 and R200 are described in the specification.

Perfluorocarbon-based antidiabetic agents

In a preliminary communication (J. Med. Chem. 1989, 32, 11-13) a series of perfluoro-N-[4-(1H-tetrazol-5yl-methyl)phenyl]alkanamides (perfluoro anilides I), designed as novel analogues of ciglitazone, were reported to possess oral antidiabetic activity in two genetic animal models of non-insulin-dependent diabetes mellitus (NIDDM): obese (ob/ob) and diabetic (db/db) mice. In this report, the results from a structure-activity relationship (SAR) study of the series I are described. Comprehensive statistical analysis among the 86 analogues screened for blood glucose lowering in ob/ob mice was achieved by a new application of a general statistical procedure which made it possible to make meaningful comparisons between more than 140 separate experiments (N = 2966). Perfluoro anilides I lowered plasma glucose in the hyperglycemic ob/ob and db/db mice but not in euglycemic normal rats. In the hyperinsulinemic ob/ob mouse, decreases in plasma insulin levels paralleled the decline in plasma glucose. Potency and efficacy in the series was shown to be dependent on the length of the perfluorocarbon chain (R(F)) of I. Optimal activity occurred with the C7 and C8 R(F) chains. The more extensive SAR studies reported here, indicated that the lipophilic R(F) chain is the most important structural element of I since neither the phenyl nor tetrazole rings present in anilides I were necessary for antihyperglycemic activity while medium length (C7-C8) R(F) chains, especially the C7F15 chain, were shown to confer antihyperglycemic activity in ob/ob mice to a wide variety of structures.